// App-Quantinova.ai

7500 : First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.

Researchers

Presenter

  • John C. Byrd

Principal Investigators

  • Paolo Ghia

  • Arnon P. Kater

  • Asher Alban Akmal Chanan-Khan

  • Richard R. Furman

  • Susan M. O'Brien

  • Mustafa Nuri Yenerel

  • rpd Ills

  • Neil E. Kay

  • Jose Antonio Garcia Marco

  • Anthony R. Mato

  • John Francis Seymour

  • Stephane Leprtre

  • Stephan Stilgenbauer

  • Tadeusz Robak

  • Priti Patel

  • Kara Higgins

  • Sophia Sohoni

  • Wojciech Jurczak

Medical Centers

  • The Ohio State University Wexner Medical Center, Columbus, OH, St. James's University Hospital, Leeds, United Kingdom

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • Amsterdam University Medical Center, Amsterdam, on behalf of Hovon, Amsterdam, Netherlands

  • Mayo Clinic, Jacksonville, FL, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA

  • Liv Hospital Ulus, Besiktas, Turkey

  • University of Debrecen, Debrecen, Hungary

  • Mayo Clinic, Rochester, MN, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain

  • University of Pennsylvania, Philadelphia, PA, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australia

  • Centre Henri Becquerel and Normandie University UNIROUEN, Rouen, France

  • University of Ulm, Ulm, Germany

  • Medical University of Lodz, Lodz, Poland

  • AstraZeneca, South San Francisco, CA

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

Locations

  • United Kingdom

  • Italy

  • Netherlands

  • Turkey

  • Hungary

  • Spain

  • Australia

  • France

  • Germany

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Cardiovascular (CVS)

Disease

  • Chronic Lymphocytic Leukemia

  • Arrhythmia

Biomarkers

  • N/A

Drug/Treatment

  • ACP-196

  • Ibrutinib

Outcome

  • N/A

Study Design

  • Randomized

  • Active Comparator

Phase

  • III

Study Id's

  • NCT02477696

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved